Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Gunter, Marc J ^a   Wang, Tao ^b   Cushman, Mary ^c   Xue, Xiaonan ^b   Wassertheil Smoller, Sylvia ^b   Strickler, Howard D ^b   Rohan, Thomas E ^b   Manson, Joann E ^d   McTiernan, Anne ^e   Kaplan, Robert C ^b   Scherer, Philipp E ^f   Chlebowski, Rowan T ^g   Snetselaar, Linda ^h   Wang, Dan ^b   Ho, Gloria Y F ^b  

^a Faculty of Medicine and MRC Health Protection Agency   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e USA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESTRADIOL; INSULIN; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; HGF PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CASE STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FIRST DEGREE RELATIVE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; COMPLICATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OBESITY; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR;

ADIPOKINES; ADIPONECTIN; AGED; BIOMARKERS, TUMOR; BODY MASS INDEX; BREAST NEOPLASMS; C-REACTIVE PROTEIN; ESTRADIOL; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; INSULIN; INTERLEUKIN-6; LEPTIN; MIDDLE AGED; OBESITY; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESISTIN; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942245589     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv169     Document Type: Article

References (40)

1. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514-527.
2. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167:2091-2102.
3. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101:48-60.
4. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616.
5. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18:2569-2578.
6. Perks CM, Holly JM. Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin North Am. 2011;40:485-507, vii.
7. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-316.
8. Tworoger SS, Eliassen AH, Kelesidis T, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92:1510-1516.
9. Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al. Adipocytokines, infam-mation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013;22:1319-1324.
10. Gaudet MM, Patel AV, Teras LR, et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet. 2013;4:156-166.
11. Cust AE, Stocks T, Lukanova A, et al. The infuence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009;113:567-576.
12. Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:1226-1236.
13. Ye J, Jia J, Dong S, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014;23:158-165.
14. Liu LY, Wang M, Ma ZB, et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS One. 2013;8:e73183.
15. Siemes C, Visser LE, Coebergh J W, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24:5216-5222.
16. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: fndings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20:15-26.
17. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Bio-markers Prev. 2006;15:381-384.
18. Zhang SM, Lin J, Cook NR, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007;99:890-894.
19. Allin KH, Bojesen SE, Nordestgaard BG. [C-reactive protein, risk of and survival after cancer-secondary publication]. Ugeskr Laeger. 2009;171:3510-3513.
20. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of infammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:2413-2418.
21. Dossus L, Jimenez-Corona A, Romieu I, et al. C-reactive protein and post-menopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control. 2014;25:533-539.
22. Hvidtfeldt UA, Gunter MJ, Lange T, et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1203-1212.
23. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61-109.
24. http://www.whiscience.org/about/about-biospecimen.php.
25. The SEER Program Code Manual. Cancer Statistics Branch, Surveillance Program, Division of Cancer Prevention and Control, National Cancer Institute, US Dept of Health and Human Services, Public Health Service, National Institutes of Health; June 1992. NIH Publication No. 92-1999. 1992.
26. SEER Program: Comparative Staging Guide for Cancer. Washington, DC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health; version 1.1, June 1993. NIH Publication 93-3640. 1993.
27. Kaplan RC, Ho G Y, Xue X, et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev. 2007;16:1291-1293.
28. Hankinson SE, Manson JE, Spiegelman D, et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995;4:649-654.
29. Missmer SA, Spiegelman D, Bertone-Johnson ER, et al. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-to 3-year period. Cancer Epidemiol Biomarkers Prev. 2006;15:972-978.
30. Gunter MJ, Cross AJ, Huang WY, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Bio-markers Prev. 2011;20:537-544.
31. Prentice RL. A Case-Cohort design for epidemiologic studies and disease prevention trials. Biometrika. 1986;73:1-11.
32. Ho GY, Wang T, Gunter MJ, et al. Adipokines linking obesity with colo-rectal cancer risk in postmenopausal women. Cancer Res. 2012;72:3029-3037.
33. Wang T, Rohan TE, Gunter MJ, et al. A prospective study of infammation markers and endometrial cancer risk in postmenopausal hormone nonus-ers. Cancer Epidemiol Biomarkers Prev. 2011;20:971-977.
34. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
35. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
36. Tsilidis KK, Branchini C, Guallar E, et al. C-reactive protein and colorec-tal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123:1133-1140.
37. Ollberding NJ, Kim Y, Shvetsov YB, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila). 2013;6:188-195.
38. Grivennikov SI, Karin M. Infammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(Suppl 1):i104-e108.
39. Hotamisligil GS. Infammation and metabolic disorders. Nature. 2006;444:860-867.
40. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.